Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2018; 9(1):92-99. doi:10.7150/jca.21357 This issue Cite

Research Paper

A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study

Dong-Fang Meng1,2*, Rui Sun3*, Li-Xia Peng1, You-Sheng Huang4, Qin Yang1, Dong-Hua Luo1,2, Wei-Han Hu3, Fang-Yun Xie3, Wei Luo3, Chong Zhao2, Ling Guo2, Hai-Qiang Mai2, Ming-Yuan Chen2, Ping Xie1,2, Li-Sheng Zheng1, Jun-Ping Yang1,2, Yan Mei1, Yuan-Yuan Qiang1, Liang Xu1, Chang-Zhi Li1, Bi-Jun Huang1, Chao-Nan Qian1,2✉, Rui Sun2✉

1. State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China;
2. Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China;
3. Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China;
4. Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510060, China.
* First two authors contribute to the study equally.

✉ Corresponding authors: Dr. Rui Sun, Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. Email: s More

Citation:
Meng DF, Sun R, Peng LX, Huang YS, Yang Q, Luo DH, Hu WH, Xie FY, Luo W, Zhao C, Guo L, Mai HQ, Chen MY, Xie P, Zheng LS, Yang JP, Mei Y, Qiang YY, Xu L, Li CZ, Huang BJ, Qian CN, Sun R. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer 2018; 9(1):92-99. doi:10.7150/jca.21357. https://www.jcancer.org/v09p0092.htm
Other styles

File import instruction

Abstract

Purpose: To compare the long-term survival outcomes and acute toxicity between locoregionally advanced nasopharyngeal carcinoma (NPC) patients who received either weekly or 3-weekly cisplatin during concurrent chemoradiotherapy (CCRT).

Methods: Between November 2008 and August 2011, 241 biopsy-proved NPC patients receiving concurrent cisplatin with intensity modulated radiotherapy (IMRT) were included. 90 patients treated with 4-7 weeks of 30-40 mg/m2 cisplatin weekly were matched with 90 patients who received two or three cycles of 80 mg/m2 cisplatin three-weekly by sex, age, T stage, N stage, Karnosky performance score (KPS). IMRT was presented to the nasopharyngeal gross target volume at 66-72 Gy/30-32 fractions and those involved neck area at 60-66 Gy/30-32 fractions.

Results: The median follow-up time was 69 months (range, 2-91 months), and the 5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) rates were 85.6% vs. 90.0% (P = 0.207), 85.6% vs. 92.6% (P = 0.152), 94.4% vs. 96.7% (P = 0.411), and 88.9% vs. 95.6% (P = 0.107) for the group treated weekly and 3-weekly cisplatin, respectively. No statistically significant survival differences were found between the two treatment groups in both univariate and multivariate analyses. The similar incidence of acute toxicities was observed between two groups.

Conclusions: Concurrent cisplatin-based chemotherapy administered weekly or three-weekly in combination with IMRT leads to similar acute toxicities and long-term survival outcomes in locoregionally advanced NPC patients.

Keywords: cisplatin regimen, nasopharyngeal carcinoma, IMRT, concurrent chemoradiotherapy.

Citation styles

APA
Meng, D.F., Sun, R., Peng, L.X., Huang, Y.S., Yang, Q., Luo, D.H., Hu, W.H., Xie, F.Y., Luo, W., Zhao, C., Guo, L., Mai, H.Q., Chen, M.Y., Xie, P., Zheng, L.S., Yang, J.P., Mei, Y., Qiang, Y.Y., Xu, L., Li, C.Z., Huang, B.J., Qian, C.N., Sun, R. (2018). A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. Journal of Cancer, 9(1), 92-99. https://doi.org/10.7150/jca.21357.

ACS
Meng, D.F.; Sun, R.; Peng, L.X.; Huang, Y.S.; Yang, Q.; Luo, D.H.; Hu, W.H.; Xie, F.Y.; Luo, W.; Zhao, C.; Guo, L.; Mai, H.Q.; Chen, M.Y.; Xie, P.; Zheng, L.S.; Yang, J.P.; Mei, Y.; Qiang, Y.Y.; Xu, L.; Li, C.Z.; Huang, B.J.; Qian, C.N.; Sun, R. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J. Cancer 2018, 9 (1), 92-99. DOI: 10.7150/jca.21357.

NLM
Meng DF, Sun R, Peng LX, Huang YS, Yang Q, Luo DH, Hu WH, Xie FY, Luo W, Zhao C, Guo L, Mai HQ, Chen MY, Xie P, Zheng LS, Yang JP, Mei Y, Qiang YY, Xu L, Li CZ, Huang BJ, Qian CN, Sun R. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer 2018; 9(1):92-99. doi:10.7150/jca.21357. https://www.jcancer.org/v09p0092.htm

CSE
Meng DF, Sun R, Peng LX, Huang YS, Yang Q, Luo DH, Hu WH, Xie FY, Luo W, Zhao C, Guo L, Mai HQ, Chen MY, Xie P, Zheng LS, Yang JP, Mei Y, Qiang YY, Xu L, Li CZ, Huang BJ, Qian CN, Sun R. 2018. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer. 9(1):92-99.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use